Patent · US Active

Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV)

US12090156B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

INSTITUTE OF OPHTHALMOLOGY AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG INSTITUTE OF OPHTHALMO · CN

Inventors

Weiyun Shi · Qingdao, CN
Qingjun Zhou · Sunnyvale, US
Hongwei Wang · Suzhou, CN
Bining Zhang · Qingdao, CN

Key dates

Filing date	Feb 15, 2023
Grant date	Sep 17, 2024
Priority date	—
Expiry date	Feb 15, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P27/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

In view of the problem that the current prevention and treatment manners for corneal neovascularization (CNV) may cause complications, the present disclosure provides an application of CB-839 in preparation of a drug for inhibiting CNV. The CB-839-loaded drug of the present disclosure can significantly inhibit CNV in mice and reduce the infiltration of inflammatory cells without obvious side effects, which makes up for the shortcoming of the prior art.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.